Testing the drug RVU120, alone and with everolimus, in children whose medulloblastoma came back or grew
Official title: Study of CDK8 Inhibitor RVU120 in Combination With Everolimus in Children With Recurrent or Progressive Group 3 or 4 Medulloblastoma
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on .
The short version
This study tests how safe a drug called RVU120 is for children with medulloblastoma that came back or kept growing.
Read our full plain-language summary
What the trial team says
This study will determine the safety and tolerability of RVU120 as a single agent and in combination with the mTOR inhibitor everolimus in children with recurrent or progressive G3 or G4 medulloblastoma and provide preliminary data regarding the efficacy of this treatment approach.
Key facts
- Registry number
- NCT07865130
- Stage of testing
- Phase 1
- Conditions studied
- Medulloblastoma Recurrent, Medulloblastoma
Where it is running
This trial lists 1 site.
-
Masovian Voivodeship
- Instytut "Pomnik - Centrum Zdrowia Dziecka", Centrum Wsparcia Pediatrycznych Badań Klinicznych (Warsaw)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.